may be included in the Commission's forthcoming report.

The meeting is open to the public. If you require a sign language interpreter, please call Sandra Saunders (202) 690–7102 by 4:30 p.m. E.D.T. on October 16, 1996.

Dated: September 24, 1996.

Linda D. Meyers,

Acting Deputy Director, Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services. [FR Doc. 96–24973 Filed 9–27–96; 8:45 am]

BILLING CODE 4160-17-M

Food and Drug Administration

[Docket No. 96F-0341]

MacMillan Bloedel, Ltd.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that MacMillan Bloedel, Ltd., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of diethylene glycol as a pulp bleaching agent for paper and paperboard intended for use in contact with food.

DATES: Written comments on the petitioner's environmental assessment by October 30, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT:

Andrew J. Zajac, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3095.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 6B4517) has been filed by MacMillan Bloedel, Ltd., c/o Camplong & Associates, Inc., P.O. Box 238, Schomberg, Ontario L0G 1T0, Canada. The petition proposes to amend the food additive regulations in § 176.170 Components of paper and paperboard in contact with aqueous and fatty foods (21 CFR 176.170) to provide for the safe use of diethylene glycol as a pulp bleaching agent for paper and paperboard intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To

encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before October 30, 1996, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: September 13, 1996. Alan M. Rulis,

Directior, Office of Premarket Approval, Center for Food Safety and Applied Nutrition. [FR Doc. 96–24966 Filed 9–27–96; 8:45 am] BILLING CODE 4160–01–F

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Meeting, Board of Scientific Counselors

Pursuant to Pub. L. 92–463, notice is hereby given of the meeting of the Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke, Division of Intramural Research on November 11–13, 1996, at the National Institutes of Health, Building 31, Rm. 6C6, 31 Center Drive, Bethesda, Maryland, 20892.

This meeting will be open to the public from 8:15 a.m. to 12:00 p.m. and from 1:30 p.m. to 5:00 p.m. on November 12th, and from 9:00 a.m. to 9:30 a.m. on November 13th, to discuss program planning and program accomplishments. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in section 552b(c)(6), Title 5, U.S.C. and section 10(d) of Pub. L. 92– 463, the meeting will be closed to the public from 8:00 p.m. to 10:00 p.m. on November 11th, and from 9:30 a.m. until adjournment on November 13th, for the review, discussion and evaluation of individual programs and projects conducted by the NINDS. The programs and discussion includes consideration of personnel qualifications and performances, the competence of individual investigators and similar items, the disclosure of which would constitute a clearly unwarranted invasion of person a privacy.

The Freedom of Information Coordinator, Mr. John Seachrist, Federal Building, Room 1012, 7550 Wisconsin Avenue, Bethesda, MD 20892, telephone (301) 496–9231 or the Executive Secretary, Dr. Story Landis, Director, Division of Intramural Research, NINDS, Building 36, Room 5A05, National Institutes of Health, Bethesda, MD 20892, telephone (301) 435-2232, will furnish a summary of the meeting and a roster of committee members upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary in advance of the meeting.

(Catalog of Federal Domestic Assistance Program No. 13.853, Clinical Basis Research; No. 13.854, Biological Basis Research)

Dated: September 24, 1996.

Paula N. Hayes,

Acting Committee Management Officer, NIH. [FR Doc. 96–25014 Filed 9–27–96; 8:45 am] BILLING CODE 4140–01–M

National Institute on Drug Abuse; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute on Drug Abuse Special Emphasis Panel meeting:

Name of Committee: Special Emphasis Panel.

Date: October 10, 1996.

Time: 8:30 a.m.

Place: Double Tree Hotel, 1750 Rockville Pike, Rockville, MD 20850.

Contact Person: Mary C. Custer, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10–22, Telephone (301) 443–2620.

Purpose Agenda: To evaluate and review grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent